Widespread Hypomethylation Occurs Early and Synergizes with Gene Amplification during Esophageal Carcinogenesis

English version České info

Although a combination of genomic and epigenetic alterations are implicated in the multistep transformation of normal squamous esophageal epithelium to Barrett esophagus, dysplasia, and adenocarcinoma, the combinatorial effect of these changes is unknown. By integrating genome-wide DNA methylation, copy number, and transcriptomic datasets obtained from endoscopic biopsies of neoplastic progression within the same individual, we are uniquely able to define the molecular events associated progression of Barrett esophagus. We find that the previously reported global hypomethylation phenomenon in cancer has its origins at the earliest stages of epithelial carcinogenesis. Promoter hypomethylation synergizes with gene amplification and leads to significant upregulation of a chr4q21 chemokine cluster and other transcripts during Barrett neoplasia. In contrast, gene-specific hypermethylation is observed at a restricted number of loci and, in combination with hemi-allelic deletions, leads to downregulatation of selected transcripts during multistep progression. We also observe that epigenetic regulation during epithelial carcinogenesis is not restricted to traditionally defined “CpG islands,” but may also occur through a mechanism of differential methylation outside of these regions. Finally, validation of novel upregulated targets (CXCL1 and 3, GATA6, and DMBT1) in a larger independent panel of samples confirms the utility of integrative analysis in cancer biomarker discovery.

Vyšlo v časopise: Widespread Hypomethylation Occurs Early and Synergizes with Gene Amplification during Esophageal Carcinogenesis. PLoS Genet 7(3): e32767. doi:10.1371/journal.pgen.1001356
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1001356

Souhrn

Zdroje

1. ZhangHY

SpechlerSJ

SouzaRF

2009 Esophageal adenocarcinoma arising in Barrett esophagus. Cancer Lett 275 170 177

2. EloubeidiMA

MasonAC

DesmondRA

El-SeragHB

2003 Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? Am J Gastroenterol 98 1627 1633

3. MontgomeryE

BronnerMP

GoldblumJR

GreensonJK

HaberMM

2001 Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 32 368 378

4. MontgomeryE

GoldblumJR

GreensonJK

HaberMM

LampsLW

2001 Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol 32 379 388

5. SpechlerSJ

2002 Clinical practice. Barrett's Esophagus. N Engl J Med 346 836 842

6. ShaheenNJ

SharmaP

OverholtBF

WolfsenHC

SamplinerRE

2009 Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 360 2277 2288

7. WangS

ZhanM

YinJ

AbrahamJM

MoriY

2006 Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis. Oncogene 25 3346 3356

8. RazviMH

PengD

DarAA

PowellSM

FriersonHFJr

2007 Transcriptional oncogenomic hot spots in Barrett's adenocarcinomas: serial analysis of gene expression. Genes Chromosomes Cancer 46 914 928

9. SelaruFM

ZouT

XuY

ShustovaV

YinJ

2002 Global gene expression profiling in Barrett's esophagus and esophageal cancer: a comparative analysis using cDNA microarrays. Oncogene 21 475 478

10. XuY

SelaruFM

YinJ

ZouTT

ShustovaV

2002 Artificial neural networks and gene filtering distinguish between global gene expression profiles of Barrett's esophagus and esophageal cancer. Cancer Res 62 3493 3497

11. PowellSM

PapadopoulosN

KinzlerKW

SmolinskiKN

MeltzerSJ

1994 APC gene mutations in the mutation cluster region are rare in esophageal cancers. Gastroenterology 107 1759 1763

12. MeltzerSJ

YinJ

HuangY

McDanielTK

NewkirkC

1991 Reduction to homozygosity involving p53 in esophageal cancers demonstrated by the polymerase chain reaction. Proc Natl Acad Sci U S A 88 4976 4980

13. HuangY

BoyntonRF

BlountPL

SilversteinRJ

YinJ

1992 Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. Cancer Res 52 6525 6530

14. JinZ

MoriY

YangJ

SatoF

ItoT

2007 Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma. Oncogene 26 6332 6340

15. LaiLA

PaulsonTG

LiX

SanchezCA

MaleyC

2007 Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array-CGH. Genes Chromosomes Cancer 46 532 542

16. PowellEL

LeoniLM

CantoMI

ForastiereAA

Iocobuzio-DonahueCA

2005 Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications. Am J Surg Pathol 29 1497 1504

17. SchulmannK

SterianA

BerkiA

YinJ

SatoF

2005 Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 24 4138 4148

18. JinZ

ChengY

GuW

ZhengY

SatoF

2009 A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res 69 4112 4115

19. SatoF

JinZ

SchulmannK

WangJ

GreenwaldBD

2008 Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features. PLoS ONE 3 e1890 doi:10.1371/journal.pone.0001890

20. PrasadGA

WangKK

HallingKC

ButtarNS

WongkeesongLM

2008 Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology 135 370 379

21. FigueroaME

ReimersM

ThompsonRF

YeK

LiY

2008 An integrative genomic and epigenomic approach for the study of transcriptional regulation. PLoS ONE 3 e1882 doi:10.1371/journal.pone.0001882

22. LearyRJ

LinJC

CumminsJ

BocaS

WoodLD

2008 Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A 105 16224 16229

23. KhulanB

ThompsonRF

YeK

FazzariMJ

SuzukiM

2006 Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Res 16 1046 1055

24. OdaM

GlassJL

ThompsonRF

MoY

OlivierEN

2009 High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers. Nucleic Acids Res 37 3829 3839

25. FigueroaME

LugthartS

LiY

Erpelinck-VerschuerenC

DengX

DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia. Cancer Cell 17 13 27

26. BaylinSB

HermanJG

GraffJR

VertinoPM

IssaJP

1998 Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72 141 196

27. ToyotaM

IssaJP

1999 CpG island methylator phenotypes in aging and cancer. Semin Cancer Biol 9 349 357

28. FazzariMJ

GreallyJM

2004 Epigenomics: beyond CpG islands. Nat Rev Genet 5 446 455

29. AlbrechtB

HausmannM

ZitzelsbergerH

SteinH

SiewertJR

2004 Array-based comparative genomic hybridization for the detection of DNA sequence copy number changes in Barrett's adenocarcinoma. J Pathol 203 780 788

30. AbdallaSI

SandersonIR

FitzgeraldRC

2005 Effect of inflammation on cyclooxygenase (COX)-2 expression in benign and malignant oesophageal cells. Carcinogenesis 26 1627 1633

31. FeinbergAP

VogelsteinB

1983 Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301 89 92

32. RodriguezJ

FrigolaJ

VendrellE

RisquesRA

FragaMF

2006 Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res 66 8462 9468

33. EhrlichM

2002 DNA methylation in cancer: too much, but also too little. Oncogene 21 5400 5413

34. DoiA

ParkIH

WenB

MurakamiP

AryeeMJ

2009 Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 41 1350 1353

35. FigueroaME

SkrabanekL

LiY

JiemjitA

FandyTE

2009 MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 114 3448 3458

36. SparmannA

Bar-SagiD

2004 Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6 447 458

37. WangD

WangH

BrownJ

DaikokuT

NingW

2006 CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med 203 941 951

38. DhawanP

RichmondA

2002 Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol 72 9 18

39. AcostaJC

O'LoghlenA

BanitoA

GuijarroMV

AugertA

2008 Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133 1006 1018

40. CoussensLM

WerbZ

2002 Inflammation and cancer. Nature 420 860 867

41. KoorstraJB

KarikariCA

FeldmannG

BishtS

RojasPL

2009 The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol Ther 8 618 626

42. HanselDE

DharaS

HuangRC

AshfaqR

DeaselM

2005 CDC2/CDK1 Expression in Esophageal Adenocarcinoma and Precursor Lesions Serves as a Diagnostic and Cancer Progression Marker and Potential Novel Drug Target. Am J Surg Pathol 29 390 399

43. MontgomeryE

MamelakAJ

GibsonM

MaitraA

SheikhS

2006 Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions. Appl Immunohistochem Mol Morphol 14 24 30

44. AlvarezH

KoorstraJB

HongSM

BoonstraJJ

DinjensWN

2008 Establishment and characterization of a bona fide barrett esophagus-associated adenocarcinoma cell line. Cancer Biol Ther 7